CHRNE

Acetylcholine receptor subunit epsilon · Q04844 · CHRNE on Sugi Atlas →

4,411 patent compounds predicted against CHRNE, 3,724 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3080697	0.43	3/20
SCHEMBL1095844	0.39	3/20
SCHEMBL3458913	0.68	2/20
SCHEMBL639023	0.50	2/20
SCHEMBL2801708	0.50	2/20
Hydrochloric Acid (SCHEMBL639237)	0.49	2/20
SCHEMBL2800503	0.49	2/20
SCHEMBL2227659	0.46	2/20
SCHEMBL2468084	0.43	2/20
Donepezil (SCHEMBL2149)	1.00	1/20
Tacrine (SCHEMBL2828)	1.00	1/20
Donepezil (SCHEMBL3516)	1.00	1/20
Nicotine (SCHEMBL20192)	1.00	1/20
(+/-)Nicotine (SCHEMBL20193)	1.00	1/20
R-Nicotine (SCHEMBL20518)	1.00	1/20
Mecamylamine (SCHEMBL34252)	1.00	1/20
Mecamylamine (SCHEMBL34253)	1.00	1/20
Nicotine (SCHEMBL308101)	1.00	1/20
2(R)-Mecamylamine (SCHEMBL308575)	1.00	1/20
Nicotine (SCHEMBL407606)	1.00	1/20

Clinical trials — most relevant to CHRNE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Multimodal Versus Opioid aNalgesia in carDiAc Surgery	PHASE4	COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Postoperative Sugammadex After COVID-19	PHASE4	UNKNOWN
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)	PHASE4	COMPLETED
Transcranial Magnetic Stimulation in Patients with Dual Disorders	PHASE3	NOT_YET_RECRUITING
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis	PHASE3	RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3	PHASE2	COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])	PHASE2	COMPLETED
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response	PHASE2	COMPLETED
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness	PHASE2	COMPLETED
Varenicline (Chantix™) for the Treatment of Alcohol Dependence	PHASE2	COMPLETED
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease	PHASE1/PHASE2	RECRUITING
M1 Schizophrenia PET Study	PHASE1	COMPLETED
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward	PHASE1	RECRUITING
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression	nan	COMPLETED
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease	nan	COMPLETED
Cognitive Effects of Mint Essential Oil	nan	COMPLETED
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection	nan	COMPLETED
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers	nan	UNKNOWN
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics	nan	WITHDRAWN
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CHRNE binder may also engage these)

Protein	Name	Similarity
P02715	—	0.998	P02715 →
P20782	—	0.996	P20782 →
P09660	—	0.995	P09660 →
CHRNB1	Acetylcholine receptor subunit beta	0.989	landscape →
P04758	—	0.983	P04758 →
P04760	—	0.983	P04760 →
P25109	—	0.983	P25109 →
P18916	—	0.982	P18916 →
P02713	—	0.982	P02713 →
P13536	—	0.978	P13536 →
CHRNG	Acetylcholine receptor subunit gamma	0.977	landscape →
P09690	—	0.976	P09690 →
P04759	—	0.967	P04759 →
P02717	—	0.965	P02717 →
CHRND	Acetylcholine receptor subunit delta	0.957	landscape →
P50572	—	0.956	P50572 →
CHRNA7	Neuronal acetylcholine receptor subunit alpha-7	0.956	landscape →
Q05941	—	0.956	Q05941 →
P02714	—	0.955	P02714 →
P54131	—	0.954	P54131 →
P23979	—	0.953	P23979 →
P02716	—	0.953	P02716 →
P25110	—	0.952	P25110 →
Q866A2	—	0.952	Q866A2 →
P49582	—	0.952	P49582 →
P49580	—	0.951	P49580 →
O70212	—	0.950	O70212 →
P47742	—	0.950	P47742 →
Q68RJ7	—	0.948	Q68RJ7 →
Q494W8	—	0.948	Q494W8 →